(NASDAQ:TOI),(NASDAQ:TOIIW), CERRITOS, Calif. and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Ascertain, a healthcare technology company pioneering agentic AI to automate administrative workflows, and The Oncology Institute, Inc. (NASDAQ: TOI), a leading value-based oncology care provider, today announced a co-development partnership to create “near-touchless” administrative workflows that reduce manual interactions between providers and payers. […]

Ascertain and The Oncology Institute Co-Develop 'Touchless' AI Automation for Oncology Administration Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workload GlobeNewswire November 13, 2025 CERRITOS, Calif. and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Ascertain, a healthcare technology company pioneering agentic AI to automate administrative workflows, and

LRN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Stride, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire November 13, 2025 SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Stride, Inc. (NYSE:

(NASDAQ:REKR), Company Achieves Third Consecutive Quarter of Positive Results Highlights: Record Quarterly Revenue: $14.2 million. Record Gross Margin: Adjusted gross margin expanded to 63% for the quarter and 55% for the nine-month period, reflecting improved mix and operational leverage. Reduced Adjusted EBITDA Loss: Adjusted EBITDA loss narrowed sharply to $1.5 million, the best in the

The following issues have been halted by CIRO Company: Galantas Gold Corporation TSX-Venture Symbol: GAL All Issues: Yes Reason: Pending News Halt Time (ET): 3:43 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and

Rekor Systems Reports Record Third Quarter 2025 Financial Results GlobeNewswire November 13, 2025 Company Achieves Third Consecutive Quarter of Positive Results Highlights: Record Quarterly Revenue: $14.2 million. Record Gross Margin: Adjusted gross margin expanded to 63% for the quarter and 55% for the nine-month period, reflecting improved mix and operational leverage. Reduced Adjusted EBITDA Loss:

(PinkSheets:BSEM),(Pinksheets:BSEM), POMPANO BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported financial results for the third quarter ended September 30, 2025. Recent Business Highlights Achieved 40% growth in product volume quarter-over-quarter

(NASDAQ:CACC), Southfield, Michigan, Nov. 13, 2025 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today the completion of a $500.0 million asset-backed non-recourse secured financing (the “Financing”). Pursuant to this transaction, we conveyed loans having a value of approximately $625.2 million to a wholly owned special

BioStem Technologies Reports Third Quarter 2025 Financial Results GlobeNewswire November 13, 2025 POMPANO BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported financial results for the third quarter ended September 30,

Credit Acceptance Announces Completion of $500.0 Million Asset-Backed Financing GlobeNewswire November 13, 2025 Southfield, Michigan, Nov. 13, 2025 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today the completion of a $500.0 million asset-backed non-recourse secured financing (the “Financing”). Pursuant to this transaction, we conveyed loans